ACTII Cooperation. In the event Amylin exercises its rights pursuant to Sections 6.2 or 6.3, above, to provide for manufacture of Four-Week Exenatide LAR other than by ACTII, ACTII shall transfer to Amylin or a third party, as appropriate, any ACTII Know-How required to enable Amylin or such third party to manufacture Four-Week Exenatide LAR and provide such assistance as is reasonably necessary to assist such manufacture and supply. Amylin shall pay ACTII the FTE Hourly Rate for time spent by ACTII personnel in such technology transfer.”
Appears in 2 contracts
Samples: Development and License Agreement (Alkermes Inc), Development and License Agreement (Amylin Pharmaceuticals Inc)
ACTII Cooperation. In the event Amylin exercises its rights pursuant to Sections 6.2 or 6.3, above, to provide for manufacture of Four-Week Exenatide LAR other than Product not by ACTII, ACTII shall transfer to Amylin or a third party, as appropriate, any ACTII Know-How required to enable Amylin or such third party to manufacture Four-Week Exenatide LAR Product and provide such assistance as is reasonably necessary to assist such manufacture and supply. Amylin shall pay ACTII the FTE Hourly Rate for time spent by ACTII personnel in such technology transfer.”
Appears in 2 contracts
Samples: Development and License Agreement (Alkermes Plc.), Development and License Agreement (Alkermes Inc)
ACTII Cooperation. In the event Amylin exercises its rights pursuant to Sections 6.2 or 6.3, above, to provide for manufacture of Four-Week Exenatide LAR other than Product not by ACTII, ACTII shall transfer to Amylin or a third party, as appropriate, any ACTII Know-How required to enable Amylin or such third party to manufacture Four-Week Exenatide LAR Product and provide such assistance as is reasonably necessary to assist such manufacture and supply. Amylin shall pay ACTII the FTE Hourly Rate for time spent by ACTII personnel in such technology transfer.”. * CONFIDENTIAL TREATMENT REQUESTED 13 14
Appears in 1 contract
Samples: Development and License Agreement (Amylin Pharmaceuticals Inc)